EGFR and plasma cell myeloma: This has included clinical evaluation of CAR-T cells directed against CD19 and CD22 for B-lymphoblastic leukemia [59], BCMA and CD19 for multiple myeloma [60], and EGFR and CD133 for cholangiocarcinoma [57].